Posts Tagged ‘innovation’

Move over, Novo Nordisk and Eli Lilly. Amgen wants a piece of the action in obesity treatment. With some obvious pride of accomplishment, Amgen unveiled results from a phase 1 study of its dual action conjugate on Saturday. This new experimental drug, AMG 133, is a molecule that combines peptides to activate GLP-1 receptors (as […]

“Can’t never could.” This old bit of Southern American wisdom aptly describes one of the startling reactions to impressive progress in obesity treatment – “we can’t do this. It will cost too much.” This reaction has been part of the landscape of obesity care for some time, so it should not be startling. But when […]

It was lovely speculation while it lasted. Ultra-processed fake meat was going to save the planet and our health. Pat Brown, the founder and former CEO of Impossible Foods, claimed he could conjure up plant-based meat that’s “vastly better” than real meat. Even McDonald’s took the bait and began testing the McPlant™ burger. But unsurprisingly […]

There’s a clue in the strained supply of new obesity and diabetes meds that most everyone is missing. For more than a year now, Novo Nordisk has been unable to produce and distribute an adequate supply of semaglutide in the form of Wegovy for the treatment of obesity. This has knock-on effects. So supply of […]

Opening ObesityWeek with a quick succession of pithy talks to set the agenda for the week seems to be a good way of getting getting the attention of the diverse audience focused on obesity. Last night, it worked. A series of talks served to focus the group on the theme for OW2022 that President Dan […]

One of the themes you will hear when ObesityWeek gets underway tomorrow in San Diego is the dramatic progress that’s coming into view with new obesity drugs. But the picture quickly becomes murky in the real world because of issues with supply and access to these new and improved obesity meds. The access to care […]

One of the hottest concepts right now in dietary fashion is plant-based diets. It’s on the way to surpassing the dominant theme of the last two decades – low-carb diets. Thus, some really exceptional claims for the benefits of plant-based diets are popping up in scientific literature. Apart from the fanciful nature of some of […]

Public discourse about obesity is often locked into the wrong debate. On one hand, a common view holds that this is a problem for which prevention is the only real answer. People must have good nutrition and active lives by default so that children will not grow into adulthood with obesity. On the other hand, […]

Be careful what you wish for, says the wisdom of the ages. It’s all about unintended consequences. Right now, policymakers all over the political spectrum are wishing to solve the problem of drug pricing in the U.S. The simple fact is that drug pricing in the U.S. puts the best, most innovative drugs out of […]

Progress keeps coming in the pharmacotherapy for obesity. This week, Novo Nordisk announced that its new combination therapy of semaglutide and cagrilintide hit all its marks in a 32-week phase 2 study of patients with diabetes and excess weight. The combination – Novo is calling it CagriSema – worked better than either semaglutide or cagrilintide […]